Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 7/2015

01.07.2015 | Review Article

The psychometric properties of cancer multisymptom assessment instruments: a clinical review

verfasst von: Aynur Aktas, Declan Walsh, Jordanka Kirkova

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Various instruments are used to assess both individual and multiple cancer symptoms. We evaluated the psychometric properties of cancer multisymptom assessment instruments.

Methods

An Ovid MEDLINE search was done. All searches were limited to adults and in English. All instruments published from 2005 to 2014 (and with at least one validity test) were included. We excluded those who only reported content validity. Instruments were categorized by the three major types of symptom measurement scales employed as follows: visual analogue (VAS), verbal rating (VRS), and numerical rating (NRS) scales. They were then examined in two areas: (1) psychometric thoroughness (number of tests) and (2) psychometric strength of evidence (validity, reliability, generalizability). We also assigned an empirical global psychometric quality score (which combined the concepts of thoroughness and strength of evidence) to rank the instruments.

Results

We analyzed 57 instruments (17 original, 40 modifications). They varied in types of scales used, symptom dimensions measured, and time frames evaluated. Of the 57, 10 used VAS, 28 VRS, and 19 NRS. The Edmonton Symptom Assessment System (ESAS), ESAS-Spanish, Hospital Anxiety and Depression Scale (HADS), Profile of Mood States (POMS), Symptom Distress Scale (SDS), M.D. Anderson Symptom Inventory (MDASI)-Russian, and MDASI-Taiwanese were the most comprehensively tested for validity and reliability. The ESAS, ESAS-Spanish, ASDS-2, Memorial Symptom Assessment Scale (MSAS)-SF, POMS, SDS, MDASI (and some translations), and MDASI-Heart Failure all showed good validity and reliability.

Conclusions

The MDASI appeared to be the best overall from a psychometric perspective. This was followed by the ESAS, ESAS-Spanish, POMS, SDS, and some MDASI translations. VRS-based instruments were most common. There was a wide range of psychometric rigor in validation. Consequently, meta-analysis was not possible. Most cancer multisymptom assessment instruments need further extensive validation to establish the excellent reliability and validity required for clinical utility and meaningful research.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
(FDA) FaDA. Food and Drug Administration (FDA) (2011) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. In: Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. hwfgd, editor. Accessed 24 May 20132011
2.
Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G et al (2007) Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 25(32):5070–5077PubMed
3.
Cleeland CS (2007) Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 37:16–21PubMed
4.
Greenhalgh J, Meadows K (1999) The effectiveness of the use of patient-based measures of health in routine practice in improving the process and outcomes of patient care: a literature review. J Eval Clin Pract 5(4):401–416PubMed
5.
6.
Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD (2007) What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 10(Suppl 2):S94–S105PubMed
7.
DeVon HA, Block ME, Moyle-Wright P, Ernst DM, Hayden SJ, Lazzara DJ et al (2007) A psychometric toolbox for testing validity and reliability. J Nurs Scholarsh 39(2):155–164PubMed
8.
Swartz RJ, Schwartz C, Basch E, Cai L, Fairclough DL, McLeod L et al (2011) The king's foot of patient-reported outcomes: current practices and new developments for the measurement of change. Qual Life Res 20(8):1159–1167PubMedCentralPubMed
9.
Kirkova J, Davis MP, Walsh D, Tiernan E, O'Leary N, LeGrand SB et al (2006) Cancer symptom assessment instruments: a systematic review. J Clin Oncol 24(9):1459–1473PubMed
10.
McDowel I (2006) Measuring health: a guide to rating scales and questionnaires. the theoretical and technical foundations of health measurement, 3rd edn. Oxford University Press, New York, pp 10–54
11.
Lipscomb J, Snyder CF, Gotay CC (2007) Cancer outcomes measurement: through the lens of the Medical Outcomes Trust framework. Qual Life Res 16(1):143–164PubMed
12.
Bowling A (2005) Theory of measurement. measuring health: a review of quality of life measurement scales, 3rd edn. Open University Press, Berkshire, pp 10–18
13.
Streiner DL, GN (2003) Validity. Health measurement scales a practical guide to their development and use, New York, United States, Oxford University Press, pp. 172-93
14.
Bourbonnais FF, Perreault A, Bouvette M (2004) Introduction of a pain and symptom assessment tool in the clinical setting–lessons learned. J Nurs Manag 12(3):194–200PubMed
15.
de Vet HC, Ader HJ, Terwee CB, Pouwer F (2005) Are factor analytical techniques used appropriately in the validation of health status questionnaires? A systematic review on the quality of factor analysis of the SF-36. Qual Life Res 14(5):1203–1218, dicussion 19-21, 23-4PubMed
16.
Mundfrom DSD, Ke TL (2005) Minimum sample size recommendations for conducting factor analysis. Int J Test 5:159–168
17.
Le Pechoux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D et al (2011) Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 22(5):1154–1163PubMedCentralPubMed
18.
Tucci RA, Bartels KL (1998) Patient use of the symptom reporting tool. Clin J Oncol Nurs 2(3):97–99PubMed
19.
Kutner JS, Kassner CT, Nowels DE (2001) Symptom burden at the end of life: hospice providers' perceptions. J Pain Symptom Manage 21(6):473–480PubMed
20.
Edmonds PM, Stuttaford JM, Penny J, Lynch AM, Chamberlain J (1998) Do hospital palliative care teams improve symptom control? Use of a modified STAS as an evaluation tool. Palliat Med 12(5):345–351PubMed
21.
Kuebler KK, KO (1998) Psychometric evaluation of an objective assessment instrument to measure pain, dyspnea and restlessness. J Palliat Care Report from 12th International Congress on Care of the Terminally ill 14:125
22.
McMillan SC, Moody LE (2003) Hospice patient and caregiver congruence in reporting patients' symptom intensity. Cancer Nurs 26(2):113–118PubMed
23.
Given B, Given CW, McCorkle R, Kozachik S, Cimprich B, Rahbar MH et al (2002) Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 29(6):949–956PubMed
24.
Nekolaichuk CL, Maguire TO, Suarez-Almazor M, Rogers WT, Bruera E (1999) Assessing the reliability of patient, nurse, and family caregiver symptom ratings in hospitalized advanced cancer patients. J Clin Oncol 17(11):3621–3630PubMed
25.
Nekolaichuk CL, Bruera E, Spachynski K, MacEachern T, Hanson J, Maguire TO (1999) A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 13(4):311–323PubMed
26.
Ivanova MO, Ionova TI, Kalyadina SA, Uspenskaya OS, Kishtovich AV, Guo H et al (2005) Cancer-related symptom assessment in Russia: validation and utility of the Russian M. D. Anderson Symptom Inventory. J Pain Symptom Manage 30(5):443–453PubMed
27.
Lin CC, Chang AP, Cleeland CS, Mendoza TR, Wang XS (2007) Taiwanese version of the M. D. Anderson symptom inventory: symptom assessment in cancer patients. J Pain Symptom Manage 33(2):180–188PubMed
28.
Moro C, Brunelli C, Miccinesi G, Fallai M, Morino P, Piazza M et al (2006) Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer 14(1):30–37PubMed
29.
Rhodes VA, McDaniel RW (1999) The index of nausea, vomiting, and Retching: a new format of the lndex of Nausea and Vomiting. Oncol Nurs Forum 26(5):889–894PubMed
30.
Wang XS, Laudico AV, Guo H, Mendoza TR, Matsuda ML, Yosuico VD et al (2006) Filipino version of the M. D. Anderson Symptom Inventory: validation and multisymptom measurement in cancer patients. J Pain Symptom Manage 31(6):542–552PubMed
31.
Yun YH, Mendoza TR, Kang IO, You CH, Roh JW, Lee CG et al (2006) Validation study of the Korean version of the M. D. Anderson Symptom Inventory. J Pain Symptom Manage 31(4):345–352PubMed
32.
Fu MR, Rhodes V, Xu B (2002) The Chinese translation of the index of nausea, vomiting, and retching. Cancer Nurs 25(2):134–140PubMed
33.
Baba K, Fransson P, Lindh J (2007) Use of a modified ESAS in cancer patients: a pilot study of patient and staff experiences. Int J Palliat Nurs 13(12):610–616PubMed
34.
Fadol A, Mendoza T, Gning I, Kernicki J, Symes L, Cleeland CS et al (2008) Psychometric testing of the MDASI-HF: a symptom assessment instrument for patients with cancer and concurrent heart failure. J Card Fail 14(6):497–507PubMed
35.
Armstrong TS, Gning I, Mendoza TR, Weinberg JS, Gilbert MR, Tortorice ML et al (2009) Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage 37(3):331–340PubMed
36.
Claessens P, Menten J, Schotsmans P, Broeckaert B (2011) Development and validation of a modified version of the Edmonton Symptom Assessment Scale in a Flemish palliative care population. Am J Hosp Palliat Care 28(7):475–482PubMed
37.
Chinda M, Jaturapatporn D, Kirshen AJ, Udomsubpayakul U (2011) Reliability and validity of a Thai version of the edmonton symptom assessment scale (ESAS-Thai). J Pain Symptom Manage 42(6):954–960PubMed
38.
Carvajal A, Centeno C, Watson R, Bruera E (2011) A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients. Eur J Cancer 47(12):1863–1872PubMed
39.
Guirimand F, Buyck J-F, Lauwers-Allot E, Revnik J, Kerguen T, Aegerter P et al (2010) Cancer-related symptom assessment in France: validation of the French M. D. Anderson Symptom Inventory. J Pain Symptom Manage 39(4):721–733PubMed
40.
Yildirim Y, Tokem Y, Bozkurt N, Fadiloglu C, Uyar M, Uslu R (2011) Reliability and validity of the Turkish version of the Memorial Symptom Assessment Scale in cancer patients. Asian Pac J Cancer Prev 12(12):3389–3396PubMed
41.
Badger TA, Segrin C, Meek P (2011) Development and validation of an instrument for rapidly assessing symptoms: the general symptom distress scale. J Pain Symptom Manage 41(3):535–548PubMedCentralPubMed
42.
Aoun SM, Monterosso L, Kristjanson LJ, McConigley R (2011) Measuring symptom distress in palliative care: psychometric properties of the Symptom Assessment Scale (SAS). J Palliat Med 14(3):315–321PubMed
43.
Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS (2004) Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer 101(8):1890–1901PubMed
44.
Mystakidou K, Cleeland C, Tsilika E, Katsouda E, Primikiri A, Parpa E et al (2004) Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology 67(3-4):203–210PubMed
45.
Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS et al (2003) Japanese version of the MD Anderson Symptom Inventory: a validation study. J Pain Symptom Manage 26(6):1093–1104PubMed
46.
Abu-Saad Huijer H, Sagherian K, Tamim H (2014) Validation of the Arabic version of the memorial symptom assessment scale among Lebanese cancer patients. J Pain Symptom Manage
47.
Kwon JH, Nam SH, Koh S, Hong YS, Lee KH, Shin SW et al (2013) Validation of the edmonton symptom assessment system in Korean patients with cancer. J Pain Symptom Manage 46(6):947–956PubMed
48.
Harding G, Cella D, Robinson D Jr, Mahadevia PJ, Clark J, Revicki DA (2007) Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes 5:34PubMedCentralPubMed
49.
Hickman SE, Tilden VP, Tolle SW (2001) Family reports of dying patients' distress: the adaptation of a research tool to assess global symptom distress in the last week of life. J Pain Symptom Manage 22(1):565–574PubMed
50.
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370PubMed
51.
Morrow GR (1984) Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research. Cancer 53(10 Suppl):2267–2280PubMed
52.
Sitzia J, Dikken C, Hughes J (1997) Psychometric evaluation of a questionnaire to document side-effects of chemotherapy. J Adv Nurs 25(5):999–1007PubMed
53.
Rhodes VA, Watson PM, Johnson MH (1984) Development of reliable and valid measures of nausea and vomiting. Cancer Nurs 7(1):33–41PubMed
54.
Barresi MJ, Shadbolt B, Byrne D, Stuart-Harris R (2003) The development of the Canberra symptom scorecard: a tool to monitor the physical symptoms of patients with advanced tumours. BMC Cancer 3:32PubMedCentralPubMed
55.
Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT (2000) The memorial symptom assessment scale short form (MSAS-SF). Cancer 89(5):1162–1171PubMed
56.
de Haes JC, van Knippenberg FC, Neijt JP (1990) Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62(6):1034–1038PubMedCentralPubMed
57.
Munro AJ, Potter S (1996) A quantitative approach to the distress caused by symptoms in patients treated with radical radiotherapy. Br J Cancer 74(4):640–647PubMedCentralPubMed
58.
Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E et al (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A(9):1326–1336PubMed
59.
Rhodes VA, McDaniel RW, Homan SS, Johnson M, Madsen R (2000) An instrument to measure symptom experience. Symptom occurrence and symptom distress. Cancer Nurs 23(1):49–54PubMed
60.
Stein KD, Denniston M, Baker F, Dent M, Hann DM, Bushhouse S et al (2003) Validation of a modified Rotterdam Symptom Checklist for use with cancer patients in the United States. J Pain Symptom Manage 26(5):975–989PubMed
61.
Watson M, ML, Maguire GP (1992) Further development of a quality of life measure for cancer patients: The Rotterdam Symptom Checklist (revised). Psychooncology 1:35-44
62.
Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89(7):1634–1646PubMed
63.
Chow E, Wong R, Connolly R, Hruby G, Franzcr, Franssen E et al (2001) Prospective assessment of symptom palliation for patients attending a rapid response radiotherapy program. feasibility of telephone follow-up. J Pain Symptom Manage 22(2):649–656PubMed
64.
McCorkle R, Quint-Benoliel J (1983) Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease. Soc Sci Med 17(7):431–438PubMed
65.
Holmes S (1991) Preliminary investigations of symptom distress in two cancer patient populations: evaluation of a measurement instrument. J Adv Nurs 16(4):439–446PubMed
66.
Bruera E, MacDonal S (1993) Audit methods: the edmonton symptom assessment system. In: Higgenson I (ed) Clinical audit in palliative care, 1st edn. Radcliffe Medical Press, Oxford, pp 61–77
67.
Morrow GR (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer Suppl 19:S72–S74PubMedCentralPubMed
68.
Slocumb EM, Cole FL (1991) A practical approach to content validation. Appl Nurs Res 4(4):192–195PubMed
69.
Brown V, Sitzia J, Richardson A, Hughes J, Hannon H, Oakley C (2001) The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy. Int J Nurs Stud 38(5):497–510PubMed
70.
Youngblood M, Williams PD, Eyles H, Waring J, Runyon S (1994) A comparison of two methods of assessing cancer therapy-related symptoms. Cancer Nurs 17(1):37–44PubMed
71.
Peruselli C, Camporesi E, Colombo AM, Cucci M, Mazzoni G, Paci E (1993) Quality-of-life assessment in a home care program for advanced cancer patients: a study using the Symptom Distress Scale. J Pain Symptom Manage 8(5):306–311PubMed
72.
Bruera E, El Osta B, Valero V, Driver LC, Pei BL, Shen L et al (2007) Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 25(23):3475–3481PubMed
73.
Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T et al (2006) Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24(13):2073–2078PubMed
74.
Ibbotson T, Maguire P, Selby P, Priestman T, Wallace L (1994) Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer 30A(1):37–40PubMed
75.
Razavi D, Delvaux N, Farvacques C, Robaye E (1990) Screening for adjustment disorders and major depressive disorders in cancer in-patients. Br J Psychiatry 156:79–83PubMed
76.
Lobchuk MM (2003) The memorial symptom assessment scale: modified for use in understanding family caregivers' perceptions of cancer patients' symptom experiences. J Pain Symptom Manage 26(1):644–654PubMed
77.
Chang VT, Hwang SS, Kasimis B, Thaler HT (2004) Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Invest 22(4):526–536PubMed
78.
Nelson JE, Meier DE, Oei EJ, Nierman DM, Senzel RS, Manfredi PL et al (2001) Self-reported symptom experience of critically ill cancer patients receiving intensive care. Crit Care Med 29(2):277–282PubMed
79.
Ewing G, Todd C, Rogers M, Barclay S, McCabe J, Martin A (2004) Validation of a symptom measure suitable for use among palliative care patients in the community: CAMPAS-R. J Pain Symptom Manage 27(4):287–299PubMed
80.
Nunnally J, I. B (1994) Psychometric theory. Psychometric theory, McGraw-Hill, New York, p. 256
81.
Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton symptom assessment scale. Cancer 88(9):2164–2171PubMed
82.
Pautex S, Berger A, Chatelain C, Herrmann F, Zulian GB (2003) Symptom assessment in elderly cancer patients receiving palliative care. Crit Rev Oncol Hematol 47(3):281–286PubMed
83.
Ewing G, Rogers M, Barclay S, McCabe J, Martin A, Campbell M et al (2006) Palliative care in primary care: a study to determine whether patients and professionals agree on symptoms. Br J Gen Pract 56(522):27–34PubMedCentralPubMed
84.
Hoekstra J, de Vos R, van Duijn NP, Schade E, Bindels PJ (2006) Using the symptom monitor in a randomized controlled trial: the effect on symptom prevalence and severity. J Pain Symptom Manage 31(1):22–30PubMed
85.
Hoekstra J, Bindels PJ, van Duijn NP, Schade E (2004) The symptom monitor. A diary for monitoring physical symptoms for cancer patients in palliative care: feasibility, reliability and compliance. J Pain Symptom Manage 27(1):24–35PubMed
86.
Richardson LA, Jones GW (2009) A review of the reliability and validity of the Edmonton Symptom Assessment System. Curr Oncol 16(1):55PubMedCentralPubMed
87.
Smith AB, Selby PJ, Velikova G, Stark D, Wright EP, Gould A et al (2002) Factor analysis of the Hospital Anxiety and Depression Scale from a large cancer population. Psychol Psychother 75(Pt 2):165–176PubMed
88.
Moorey S, Greer S, Watson M, Gorman C, Rowden L, Tunmore R et al (1991) The factor structure and factor stability of the hospital anxiety and depression scale in patients with cancer. Br J Psychiatry 158:255–259PubMed
89.
Vignaroli E, Pace EA, Willey J, Palmer JL, Zhang T, Bruera E (2006) The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J Palliat Med 9(2):296–303PubMed
90.
Williams PD, Ducey KA, Sears AM, Williams AR, Tobin-Rumelhart SE, Bunde P (2001) Treatment type and symptom severity among oncology patients by self-report. Int J Nurs Stud 38(3):359–367PubMed
91.
Baker F, Denniston M, Zabora J, Polland A, Dudley WN (2002) A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology 11(4):273–281PubMed
92.
Reddy S, Bruera E, Pace E, Zhang K, Reyes-Gibby CC (2007) Clinically important improvement in the intensity of fatigue in patients with advanced cancer. J Palliat Med 10(5):1068–1075PubMed
93.
Philip J, Smith WB, Craft P, Lickiss N (1998) Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. Support Care Cancer 6(6):539–541PubMed
94.
Lund I, Lundeberg T, Sandberg L, Budh CN, Kowalski J, Svensson E (2005) Lack of interchangeability between visual analogue and verbal rating pain scales: a cross sectional description of pain etiology groups. BMC Med Res Methodol 5:31PubMedCentralPubMed
95.
Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA (2007) A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 109(4):787–795PubMed
96.
Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8(2):135–160PubMed
97.
Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 2(5):472–483PubMed
98.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMed
99.
Huskisson E (1983) Visual analogue scales. In: Melzack R (ed) Pain management and assessment. Raven, New York, pp 33–37
100.
Hinds PS, Schum L, Srivastava DK (2002) Is clinical relevance sometimes lost in summative scores? West J Nurs Res 24(4):345–353PubMed
101.
Vickers AJ (2004) Statistical considerations for use of composite health-related quality-of-life scores in randomized trials. Qual Life Res 13(4):717–723PubMedCentralPubMed
102.
Watanabe S, Nekolaichuk C, Beaumont C, Mawani A (2009) The Edmonton symptom assessment system—what do patients think? Support Care Cancer 17(6):675–683PubMed
103.
Holmes S (1989) Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud 26(1):69–79PubMed
104.
Sutherland HJ, Walker P, Till JE (1988) The development of a method for determining oncology patients' emotional distress using linear analogue scales. Cancer Nurs 11(5):303–308PubMed
105.
Morrow GR, Chiarello RJ, Derogatis LR (1978) A new scale for assessing patients' psychosocial adjustment to medical illness. Psychol Med 8(4):605–610PubMed
106.
Pud D (2014) The psychometric properties of the Hebrew version of the Memorial Symptom Assessment Scale (MSAS-Heb) in breast cancer patients. J Pain Symptom Manage
107.
Browall M, Kenne Sarenmalm E, Nasic S, Wengstrom Y, Gaston-Johansson F (2013) Validity and reliability of the Swedish version of the Memorial Symptom Assessment Scale (MSAS): an instrument for the evaluation of symptom prevalence, characteristics, and distress. J Pain Symptom Manage 46(1):131–141PubMed
108.
McCorkle R, Young K (1978) Development of a symptom distress scale. Cancer Nurs 1(5):373–378PubMed
109.
Chow E, Davis L, Holden L, Tsao M, Danjoux C (2005) Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manage 30(1):18–23PubMed
110.
Chow E, Fan G, Hadi S, Filipczak L (2007) Symptom clusters in cancer patients with bone metastases. Support Care Cancer 15(9):1035–1043PubMed
111.
Stromgren AS, Groenvold M, Pedersen L, Olsen AK, Sjogren P (2002) Symptomatology of cancer patients in palliative care: content validation of self-assessment questionnaires against medical records. Eur J Cancer 38(6):788–794PubMed
112.
Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS (2007) Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer 110(7):1629–1640
113.
Yamagishi A, Morita T, Miyashita M, Kimura F (2009) Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy. J Pain Symptom Manage 37(5):823–830PubMed
114.
Chen ML, Tseng HC (2006) Symptom clusters in cancer patients. Support Care Cancer 14(8):825–830PubMed
115.
Chen ML, Lin CC (2007) Cancer symptom clusters: a validation study. J Pain Symptom Manage 34(6):590–599PubMed
Metadaten
Titel
The psychometric properties of cancer multisymptom assessment instruments: a clinical review
verfasst von
Aynur Aktas
Declan Walsh
Jordanka Kirkova
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2732-7

Weitere Artikel der Ausgabe 7/2015

Supportive Care in Cancer 7/2015 Zur Ausgabe

Original Article

Coping with physical and psychological symptoms: a qualitative study of advanced lung cancer patients and their family caregivers

Original Article

Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer

Original Article

Design, development, and feasibility of a spanish-language cancer survivor support group

Original Article

Seroprevalence of HSV-1/2 and correlation with aggravation of oral mucositis in patients with squamous cell carcinoma of the head and neck region submitted to antineoplastic treatment

Original Article

Follow-up care instructions, treatment summaries, and cancer survivors’ receipt of follow-up health care and late/long term effects

Original Article

Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise